From the publishers of JADPRO

HR+ HER2- Breast Cancer Resource Center

Advertisement

Social determinants of health and other predictors in initiation of treatment with CDK4/6 inhibitors for HR+/HER2- metastatic breast cancer

Last Updated: Monday, July 29, 2024

Although CDK4/6 inhibitors have become the standard of care in HR+ HER2- breast cancer, there are barriers to treatment initiation. Researchers used a retrospective cohort design to evaluate social determinants of health and other factors associated with the initiation of CDK4/6 inhibitors among Medicare patients. They found that older patients who live in areas with high median household income and a high proportion of Medicare-only coverage had higher rates of initiating CDK4/6 inhibitors in comparison to patients living in areas with low median household income and a low proportion of Medicare-only coverage. They concluded that there is a need for policy intervention to address the inequitable access to this standard-of-care treatment. 

Cancers (Basel)
Advertisement
News & Literature Highlights

The Breast

Switching to T-DM1 remains justified in patients with HER2-negative residual invasive breast cancer after neoadjuvant therapy

Scientific Reports

Increased primary breast tumor expression of CD73 is associated with development of bone metastases and is a potential biomarker for adjuvant bisphosphonate use

Frontiers in Oncology

Cryoablation in the treatment of early breast cancer: A comprehensive analysis

JAMA Oncology

Breast cancer index in premenopausal women with early-stage hormone receptor–positive breast cancer

Anticancer Research

Cardioprotective effect of pegfilgrastim on chemotherapy-induced cardiotoxicity in preoperative chemotherapy for breast cancer

The Breast

Systematic literature review and trial-level meta-analysis of aromatase inhibitors vs tamoxifen in patients with HR+/HER2- early breast cancer

Cancers (Basel)

CDK4/6 as a therapeutic target in HR+/HER2- breast cancer cells—Current treatment status

Clinical Cancer Research

Identification of early-stage breast cancer with minimal risk of recurrence by Breast Cancer Index

Journal of Clinical Oncology

INAVO120: Phase III trial final overall survival (OS) analysis of first-line inavolisib (INAVO)/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR+), HER2-negative (HER2–), endocrine-resistant advanced breast cancer (aBC)

Journal of Clinical Oncology

VERITAC-2: A global, randomized phase 3 study of ARV-471, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, vs fulvestrant in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer

Advertisement
Advertisement